-$0.57 Earnings Per Share Expected for Aquinox Pharmaceuticals Inc (AQXP) This Quarter

Wall Street analysts forecast that Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) will report earnings per share of ($0.57) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aquinox Pharmaceuticals’ earnings. Aquinox Pharmaceuticals posted earnings per share of ($0.39) in the same quarter last year, which would indicate a negative year over year growth rate of 46.2%. The firm is expected to report its next earnings results on Tuesday, May 9th.

On average, analysts expect that Aquinox Pharmaceuticals will report full year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.43) to ($2.30). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.40) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Aquinox Pharmaceuticals.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Thursday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.03.

A number of research analysts recently weighed in on AQXP shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Aquinox Pharmaceuticals in a research report on Tuesday, March 21st. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $21.17.

TRADEMARK VIOLATION WARNING: This report was published by sleekmoney and is owned by of sleekmoney. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at http://sleekmoney.com/0-57-earnings-per-share-expected-for-aquinox-pharmaceuticals-inc-aqxp-this-quarter/1739596.html.

Hedge funds have recently made changes to their positions in the company. Eventide Asset Management LLC bought a new stake in shares of Aquinox Pharmaceuticals during the fourth quarter valued at approximately $2,889,000. BlackRock Advisors LLC raised its stake in shares of Aquinox Pharmaceuticals by 31.1% in the third quarter. BlackRock Advisors LLC now owns 530,373 shares of the company’s stock valued at $7,086,000 after buying an additional 125,798 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $140,762,000. BlackRock Group LTD raised its stake in shares of Aquinox Pharmaceuticals by 15.9% in the third quarter. BlackRock Group LTD now owns 232,002 shares of the company’s stock valued at $3,100,000 after buying an additional 31,902 shares in the last quarter. Finally, RA Capital Management LLC raised its stake in shares of Aquinox Pharmaceuticals by 29.6% in the third quarter. RA Capital Management LLC now owns 2,191,977 shares of the company’s stock valued at $29,285,000 after buying an additional 500,000 shares in the last quarter. 97.78% of the stock is currently owned by institutional investors and hedge funds.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.77% on Monday, hitting $14.25. 134,001 shares of the company’s stock were exchanged. Aquinox Pharmaceuticals has a 12 month low of $6.01 and a 12 month high of $19.97. The stock’s 50 day moving average is $16.45 and its 200 day moving average is $15.42. The firm’s market cap is $333.78 million.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Get a free copy of the Zacks research report on Aquinox Pharmaceuticals (AQXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/0-57-earnings-per-share-expected-for-aquinox-pharmaceuticals-inc-aqxp-this-quarter/1739596.html

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *